Quitting smoking is hard. A Medicare change may push doctors to give more help
-
By
-
Sarah Todd
-
July 17, 2026
By
Sarah Todd
July 17, 2026
by Sarah Todd
July 17, 2026
In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.
July 16, 2026
According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.
July 14, 2026